Cargando…
Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use
BACKGROUND: Vasodilator-stimulated phosphoprotein (VASP) mediates focal adhesion, actin filament binding and polymerization in a variety of cells, thereby inhibiting cell movement. Phosphorylation of VASP via cAMP and cGMP dependent protein kinases releases this "brake" on cell motility. T...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1388207/ https://www.ncbi.nlm.nih.gov/pubmed/16480498 http://dx.doi.org/10.1186/1465-9921-7-25 |
_version_ | 1782126898274369536 |
---|---|
author | Hastie, Annette T Wu, Min Foster, Gayle C Hawkins, Gregory A Batra, Vikas Rybinski, Katherine A Cirelli, Rosemary Zangrilli, James G Peters, Stephen P |
author_facet | Hastie, Annette T Wu, Min Foster, Gayle C Hawkins, Gregory A Batra, Vikas Rybinski, Katherine A Cirelli, Rosemary Zangrilli, James G Peters, Stephen P |
author_sort | Hastie, Annette T |
collection | PubMed |
description | BACKGROUND: Vasodilator-stimulated phosphoprotein (VASP) mediates focal adhesion, actin filament binding and polymerization in a variety of cells, thereby inhibiting cell movement. Phosphorylation of VASP via cAMP and cGMP dependent protein kinases releases this "brake" on cell motility. Thus, phosphorylation of VASP may be necessary for epithelial cell repair of damage from allergen-induced inflammation. Two hypotheses were examined: (1) injury from segmental allergen challenge increases VASP phosphorylation in airway epithelium in asthmatic but not nonasthmatic normal subjects, (2) regular in vivo β(2)-agonist use increases VASP phosphorylation in asthmatic epithelium, altering cell adhesion. METHODS: Bronchial epithelium was obtained from asthmatic and non-asthmatic normal subjects before and after segmental allergen challenge, and after regularly inhaled albuterol, in three separate protocols. VASP phosphorylation was examined in Western blots of epithelial samples. DNA was obtained for β(2)-adrenergic receptor haplotype determination. RESULTS: Although VASP phosphorylation increased, it was not significantly greater after allergen challenge in asthmatics or normals. However, VASP phosphorylation in epithelium of nonasthmatic normal subjects was double that observed in asthmatic subjects, both at baseline and after challenge. Regularly inhaled albuterol significantly increased VASP phosphorylation in asthmatic subjects in both unchallenged and antigen challenged lung segment epithelium. There was also a significant increase in epithelial cells in the bronchoalveolar lavage of the unchallenged lung segment after regular inhalation of albuterol but not of placebo. The haplotypes of the β(2)-adrenergic receptor did not appear to associate with increased or decreased phosphorylation of VASP. CONCLUSION: Decreased VASP phosphorylation was observed in epithelial cells of asthmatics compared to nonasthmatic normals, despite response to β-agonist. The decreased phosphorylation does not appear to be associated with a particular β(2)-adrenergic receptor haplotype. The observed decrease in VASP phosphorylation suggests greater inhibition of actin reorganization which is necessary for altering attachment and migration required during epithelial repair. |
format | Text |
id | pubmed-1388207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-13882072006-03-04 Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use Hastie, Annette T Wu, Min Foster, Gayle C Hawkins, Gregory A Batra, Vikas Rybinski, Katherine A Cirelli, Rosemary Zangrilli, James G Peters, Stephen P Respir Res Research BACKGROUND: Vasodilator-stimulated phosphoprotein (VASP) mediates focal adhesion, actin filament binding and polymerization in a variety of cells, thereby inhibiting cell movement. Phosphorylation of VASP via cAMP and cGMP dependent protein kinases releases this "brake" on cell motility. Thus, phosphorylation of VASP may be necessary for epithelial cell repair of damage from allergen-induced inflammation. Two hypotheses were examined: (1) injury from segmental allergen challenge increases VASP phosphorylation in airway epithelium in asthmatic but not nonasthmatic normal subjects, (2) regular in vivo β(2)-agonist use increases VASP phosphorylation in asthmatic epithelium, altering cell adhesion. METHODS: Bronchial epithelium was obtained from asthmatic and non-asthmatic normal subjects before and after segmental allergen challenge, and after regularly inhaled albuterol, in three separate protocols. VASP phosphorylation was examined in Western blots of epithelial samples. DNA was obtained for β(2)-adrenergic receptor haplotype determination. RESULTS: Although VASP phosphorylation increased, it was not significantly greater after allergen challenge in asthmatics or normals. However, VASP phosphorylation in epithelium of nonasthmatic normal subjects was double that observed in asthmatic subjects, both at baseline and after challenge. Regularly inhaled albuterol significantly increased VASP phosphorylation in asthmatic subjects in both unchallenged and antigen challenged lung segment epithelium. There was also a significant increase in epithelial cells in the bronchoalveolar lavage of the unchallenged lung segment after regular inhalation of albuterol but not of placebo. The haplotypes of the β(2)-adrenergic receptor did not appear to associate with increased or decreased phosphorylation of VASP. CONCLUSION: Decreased VASP phosphorylation was observed in epithelial cells of asthmatics compared to nonasthmatic normals, despite response to β-agonist. The decreased phosphorylation does not appear to be associated with a particular β(2)-adrenergic receptor haplotype. The observed decrease in VASP phosphorylation suggests greater inhibition of actin reorganization which is necessary for altering attachment and migration required during epithelial repair. BioMed Central 2006 2006-02-15 /pmc/articles/PMC1388207/ /pubmed/16480498 http://dx.doi.org/10.1186/1465-9921-7-25 Text en Copyright © 2006 Hastie et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Hastie, Annette T Wu, Min Foster, Gayle C Hawkins, Gregory A Batra, Vikas Rybinski, Katherine A Cirelli, Rosemary Zangrilli, James G Peters, Stephen P Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use |
title | Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use |
title_full | Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use |
title_fullStr | Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use |
title_full_unstemmed | Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use |
title_short | Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use |
title_sort | alterations in vasodilator-stimulated phosphoprotein (vasp) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1388207/ https://www.ncbi.nlm.nih.gov/pubmed/16480498 http://dx.doi.org/10.1186/1465-9921-7-25 |
work_keys_str_mv | AT hastieannettet alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse AT wumin alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse AT fostergaylec alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse AT hawkinsgregorya alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse AT batravikas alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse AT rybinskikatherinea alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse AT cirellirosemary alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse AT zangrillijamesg alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse AT petersstephenp alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse |